06:57 AM EDT, 04/17/2026 (MT Newswires) -- Kura Oncology ( KURA ) said Friday that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.

Results also showed a "manageable" safety profile in all patients across multiple dose levels, including full dose cabozantinib, the company said.

The study showed an objective response rate of 44%, with a 94% disease control rate across all doses tested, with tumor shrinkage observed in 75% of patients.

Kura said the latest findings are consistent with data presented at the 2025 European Society for Medical Oncology and in earlier data disclosures supporting the potential of darlifarnib to "enhance" the activity of VEGFR-targeted therapies and to address mechanisms of resistance.

The company's shares were up 7.7% in premarket activity.